*Sponsored
Jeff Ackerman Initiates Coverage On Actuate Therapeutics (Nasdaq: ACTU) Starting This Morning—Wednesday, August 6, 2025
(ACTU) Comes Backed By Several Potential Catalysts Including…
Limited Float: (ACTU) Has Less Than 6Mn Shares—Which Could Lead To
The Potential For Heightened Volatility And Big Swings
Index Milestone: (ACTU) Recently Secured Inclusion In Both The Russell 3000® And Russell 2000® Indexes
Analyst Targets In Focus: (ACTU) Receives Coverage From Two Analysts With The Average Target Suggesting Over 180% Upside Potential
Take A Look At (ACTU) This Morning—While It's Still Early…
August 6, 2025 Trending Now | (ACTU) Flashes Multiple Bullish Signals On Approx. 12% Move Dear Reader, Something's stirring on the screens this morning, and it's hard to ignore. Right now, (ACTU) is flashing multiple bullish signals on TradingView's technical analysis dashboard. (ACTU) tapped $8.22, marking an approximate 12% move from yesterday's $7.31 close. Just moments ago, (ACTU) revealed a high‑profile collaboration with $15B Incyte Corporation and the University of Pittsburgh's UPMC Hillman Cancer Center — launching a new Phase 1b trial in advanced pancreatic cancer. This study pairs (ACTU)'s elraglusib with Incyte's PD‑1 inhibitor retifanlimab and mFOLFIRINOX in a bid to create a synergistic, immune‑modulating frontline treatment approach for one of the most difficult‑to‑treat cancers. With a track record of promising survival data in earlier studies, and now the backing of a major biopharma partner, this latest move could mark a pivotal step forward in (ACTU)'s clinical development strategy. See full story here. If you missed my report from just a few minutes, keep reading to quickly get up to speed on (ACTU) why we're so excited to be bringing this to you today. In the fast‑moving world of cancer therapeutics, one clinical‑stage biopharmaceutical team has begun drawing attention for an approach aimed at some of the toughest forms of the disease. By focusing on key molecular pathways, they're working to open doors where traditional treatments often reach their limits. Recent progress includes trial data showing survival gains in advanced, hard‑to‑treat cases — alongside fresh recognition through inclusion in both the Russell 3000® and Russell 2000® Indexes. Add to that a float under 6Mn shares — and two independent analyst targets that average over 180% upside potential — and this situation becomes hard to ignore. Today, that setup puts one name at the top of our watchlist:
Actuate Therapeutics, Inc. (Nasdaq: ACTU)
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate's lead investigational dr-ug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer dr-ugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function. And based on these 5 potential catalysts, (Nasdaq: ACTU) has taken over the top spot on my watchlist this week. Take a look:
#1. A low float could lead to heightened volatility potential. #2. Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas. #3. Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial. #4. Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes. #5. MarketBeat is reporting two separate, strong analyst targets. But more on those in a second...
Key Company Highlights - Important Details Surrounding (Nasdaq: ACTU)
(1.) Advancing a potentially class-leading GSK-3β inhibitor, elraglusib with a novel, multimodal MOA, in multiple advanced cancer Phase 2 trials. (2.) Clinical responses (CRs/PRs) and Disease Control observed across cancer histologies Extended survival and increased responses are observed in mPDAC and relapsed/refractory Ewing sarcoma. Preliminary evidence of clinical benefit has also been observed in patients with metastatic melanoma and relapsed/refractory colorectal and lung cancer. (3.) Oral version of elraglusib successfully evaluated in Healthy Volunteer Phase 1. Phase 1 dose escalation study planned in advanced cancer patients. (4.) Broad composition of matter IP protection and development incentives. Orphan Drug Designations for pancreatic and other cancer types; Fast Track Designation for pancreatic cancer. Strategic Pipeline Growth for GSK-3β Associated Diseases
Grab Sources Here: ACTU Presentation. ==== These (Nasdaq: ACTU) Potential Breakout Catalysts Require Full Attention!
#1. A low float could lead to heightened volatility potential.
According to info from the Yahoo website, (ACTU) has a fairly low float. The website reports this profile to have roughly 5.98Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If positive company news appears in the midway part of 2025, could this low float potential help provide a breakout spark?
#2. Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas.
"Refractory and resistant EWS is one of the most aggressive and underserved cancers affecting children and young adults with very low survival rates," said Dr. Andrew Mazar, Actuate's Scientific Co-founder and Chief Operating Officer. "To observe complete responses in this setting is highly unexpected, and these exceptional early results position elraglusib as a potential first-in-class therapy option in an indication where no approved targeted therapies currently exist."
"We are highly encouraged by the responses observed in refractory and resistant EWS, a disease where treatment options are extremely limited beyond frontline chemotherapy," said Daniel Schmitt, President & Chief Executive Officer of Actuate. "With these promising clinical signals in hand, we are advancing our development plans focused on EWS by pursuing a Phase 2 trial and plan to meet with regulators to discuss potential registration path in this indication."
#3. Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial.
"We are highly encouraged by the significant clinical benefit provided by elraglusib demonstrated in this study," said Daniel Schmitt, President & Chief Executive Officer of Actuate. "Patients who received at least one cycle – or 4 weeks – of elraglusib showed a rapid and meaningful survival benefit, including a near doubling of the 1-year overall survival and 43% reduction in the risk of death compared to control. Separately, in the subgroup of patients with liver metastases, a population with historically poor prognosis, we observed a more than 2.5-fold improvement in 1-year OS with a 38% reduction in risk of death. These results underscore the potential of elraglusib to generate rapid and durable benefit in high-risk patients, which could be highly impactful in future development and commercial pathways."
#4. Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes.
"Inclusion in the Russell 3000® and 2000® Indexes represents a significant milestone for Actuate and reflects the company's strong momentum since our IPO last year," said Daniel Schmitt, President & Chief Executive Officer of Actuate. "It comes on the heels of very positive topline Phase 2 data in mPDAC, which showed that the trial met its primary endpoint, demonstrating a clinically meaningful increase in median overall survival (mOS) of 10.1 months compared to 7.2 months (p = 0.01), with a 37% reduction in the risk of death (HR = 0.63), reinforcing the therapeutic potential of our lead candidate, elraglusib. This recognition not only elevates our visibility within the in-vest-ment community but also validates our platform and strategic direction. As we advanced the development of elraglusib, we believe this is a pivotal moment that further positions Actuate for long-term growth and value creation."
#5. MarketBeat is reporting two separate, strong analyst targets.
Take a look:
As you can see above, (ACTU) may have triple-digit upside potential from current levels according to these two analyst targets of $21 and $20, respectively. ==== Recap - 5 Potential Catalysts Put (Nasdaq: ACTU) On Radar
#1. A low float could lead to heightened volatility potential. #2. Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas. #3. Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial. #4. Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes. #5. MarketBeat is reporting two separate, strong analyst targets. ==== Coverage is officially initiated on Actuate Therapeutics, Inc. (Nasdaq: ACTU), starting this morning—Wednesday, August 6, 2025. Stay tuned — We''ll be watching closely to see how the market responds to this new collaboration and the potential it holds for (ACTU)'s lead program. Right now, (ACTU) is flashing multiple bullish signals on TradingView's technical analysis dashboard. (ACTU) tapped $8.22, marking an approximate 12% move from yesterday's $7.31 close. Watch for my next update—it could be hitting any moment. Sincerely, Jeff Ackerman Managing Editor Stock News Trends | 
Post a Comment
Post a Comment